There is no clear winner yet among bispecific antibodies targeting B-cell maturation antigen (BCMA) in the treatment of multiple myeloma, based on data presented virtually during the American Society of Hematology (ASH) annual meeting. However, these bispecifics are beginning to move into Phase II trials that may show whether they can compete with highly effective chimeric antigen receptor T-cell (CAR-T) therapies that likely will be the next BCMA-targeting modality to reach the market.
ASH 2020: Bispecifics Battle For Share Of BCMA Market In Myeloma
CAR-T Therapies Will Beat T-Cell Engagers To Market
Response rates for multiple myeloma patients treated with BCMA-targeting bispecific antibodies are lower than for CAR-T therapies, but adverse event rates are lower for the off-the-shelf treatments.
